

A

Docket # PF-0346-1 DIV



"Express Mail" mailing label number EL 315 814 217 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 9-27-99

By:

Nancy Ramos

Printed: NANCY RAMOS



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)**

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No.08/897,097, filed on July 18, 1997, entitled T-CELL RECEPTOR BETA-LIKE PROTEIN.

1. X Enclosed is a copy of the prior application, U. S. Application Serial No.08/897,097 filed July 18, 1997, including the oath or declaration as originally signed.
2. X With regard to the requirement of 37 CFR 1.821(d) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants submit that the computer readable form of the "Sequence Listing" in the instant divisional application is identical with that filed for Serial No. 08/897,097, filed July 18, 1997, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. 08/897,097 as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
3. X Cancel in this application original claims 3-12 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
4. X The inventor(s) of the invention being claimed in this application is (are): Jennifer L. Hillman and Neil C. Corley.

5. X In accordance with 37 CFR 1.63(d) a copy of the originally signed declaration showing applicant's/applicants' signature(s) as filed on July 18, 1997 is enclosed.
6. X Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application serial number 08/897,097, filed July 18, 1997."
7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity		Basic Fee
				Rate	Fee	\$760.00
Total Claims	13	-20	0	x \$18		\$0
Indep. Claims	3	-3	0	x \$78		\$0
— Multiple Dependent Claim(s), if any				+ \$260		\$0

TOTAL FILING FEE \$ 760.00

8. ___ An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
9. X Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108 in the amount of \$760.00.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Incyte Pharmaceuticals, Inc. Account No. 09-0108.

Duplicate copies of these papers are enclosed.

10. ___ New formal drawings are enclosed.
11. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc., recorded on July 18, 1997, at reel 8648/frame 0077.
12. X A preliminary amendment is enclosed.
13. X Also enclosed Return Postcard; Information Disclosure Statement (2pp, in duplicate); List of References Cited by Applicant (2 pp, in duplicate); Revocation of Power of Attorney and Appointment of New Attorneys (2 pp); Copy of Previously Submitted Associate Power of Attorney (1 pp).

14. X The power of attorney of the prior application is to:

Lucy J. Billings
Michael C. Cerrone

Reg. No. 36,749
Reg. No. 39,132

X The associate power of attorney in the prior application is to:

Colette C. Muenzen
Sheela Mohan-Peterson
Karen J. Zeller

Reg. No. 39,784
Reg. No. 41,201
Reg. No. 37,071

- a. An associate power of attorney is attached.
- b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

David G. Streeter, Ph.D.
INCYTE PHARMACEUTICALS, INC.
PATENT DEPARTMENT
3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555, Fax: (650) 849-8886

Date: September 22, 1999 By: David G. Streeter
David G. Streeter, Ph. D.
Reg. No. 43,168
Direct Dial Telephone: (650) 845-5741

- Inventor(s)
 Assignee of complete interest
X Attorney or agent of record
 Filed under 37 CFR 1.34(a)
Registration number if acting under 37 CFR 1.34(a)

"Express Mail" mailing label number EL315 814 217 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 9-27-99

By: Nancy Ramon

Printed: NANCY RAMON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: T-CELL RECEPTOR PROTEIN (as amended)

Serial No.: To Be Assigned

Filing Date:

Herewith

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the application as follows:

IN THE SPECIFICATION

At page 15, line 5, delete "Fig. 1" and insert --Figure 1A, 1B, 1C, and 1D--.

At page 17, line 23, delete "devise" and insert --device--.

At page 23, line 15, after "aminoglycosides" insert a comma --,--.

At page 25, line 29, delete "Merrifield" and insert --(Merrifield--.

At page 28, line 28, delete "immunoglobulin" and insert --immunoglobulin--.

At page 29, line 28, delete "retro viruses" and insert --retroviruses--.

At page 33, line 18, delete "Hanks's" and insert --Hanks'--.

At page 34, line 27, delete "therapeutic and toxic" and insert --toxic and therapeutic--.

At page 36, line 7, delete "subject, control and disease, samples" and insert --subject samples, control and disease--.

At page 43, line 16, delete "(specimen #0065B; Mayo Clinic, Rochester MN)".

IN THE CLAIMS

Please cancel claims 3-12 without prejudice.

Please amend claim 1 as follows.

1. (Once Amended) A substantially purified T-cell receptor beta[-like] protein comprising the amino acid sequence of SEQ ID NO:1, an allelic variant thereof, or a fragment[s] thereof.

Please add new claims 22 and 23 as follows.

22. (New) A method for using a protein to screen a library of other molecules for a molecule which specifically binds the protein, the method comprising:
 - (a) combining the protein of claim 1 with the library of molecules under conditions suitable to allow complex formation, and
 - (b) detecting complex formation, wherein the presence of the complex identifies a molecule which specifically binds the protein.
23. (New) The library of claim 22, wherein the library is selected from the group consisting of inhibitors, peptides, antibodies, immunoglobulins, and pharmaceutical agents.

REMARKS

The above amendments correct inadvertent typographical and grammatical errors in the specification. The amendment to claim 1 further defines and limits the term "variant". Support for this amendment is found throughout the specification, for example at page 6, lines 16-23, and

at page 36, lines 17-24. Support for new claim 22 is found, for example, at page 42, line 17 through page 43, line 5, and at page 52, lines 7-12, and for claim 23 at page 18, lines 19-23, at page 27, lines 21-23, and at page 28, line 30 through page 29, line 3. No new matter has been added by these amendments. Applicants respectfully request entry of the present amendment.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date:

September 27, 1989

David G. Streeter

David G. Streeter, Ph. D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

"Express Mail" mailing label number EL 315 814 217 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 9-27-99

By: Nancy Rames

Printed: NANCY RAMES

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: T-CELL RECEPTOR PROTEIN (as amended)

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the application as follows:

IN THE SPECIFICATION

At page 15, line 5, delete "Fig. 1" and insert --Figure 1A, 1B, 1C, and 1D--.

At page 17, line 23, delete "devise" and insert --device--.

At page 23, line 15, after "aminoglycosides" insert a comma --,--.

At page 25, line 29, delete "Merrifield" and insert --(Merrifield--.

At page 28, line 28, delete "immunoglobulin" and insert --immunoglobulin--.

At page 29, line 28, delete "retro viruses" and insert --retroviruses--.

At page 33, line 18, delete "Hanks's" and insert --Hanks'--.

At page 34, line 27, delete "therapeutic and toxic" and insert --toxic and therapeutic--.

At page 36, line 7, delete "subject, control and disease, samples" and insert --subject samples, control and disease--.

At page 43, line 16, delete "(specimen #0065B; Mayo Clinic, Rochester MN)".

IN THE CLAIMS

Please cancel claims 3-12 without prejudice.

Please amend claim 1 as follows.

1. (Once Amended) A substantially purified T-cell receptor beta[-like] protein comprising the amino acid sequence of SEQ ID NO: 1, an allelic variant thereof, or a fragment[s] thereof.

Please add new claims 22 and 23 as follows.

22. (New) A method for using a protein to screen a library of other molecules for a molecule which specifically binds the protein, the method comprising:
 - (a) combining the protein of claim 1 with the library of molecules under conditions suitable to allow complex formation, and
 - (b) detecting complex formation, wherein the presence of the complex identifies a molecule which specifically binds the protein.
23. (New) The library of claim 22, wherein the library is selected from the group consisting of inhibitors, peptides, antibodies, immunoglobulins, and pharmaceutical agents.

REMARKS

The above amendments correct inadvertent typographical and grammatical errors in the specification. The amendment to claim 1 further defines and limits the term "variant". Support for this amendment is found throughout the specification, for example at page 6, lines 16-23, and

at page 36, lines 17-24. Support for new claim 22 is found, for example, at page 42, line 17 through page 43, line 5, and at page 52, lines 7-12, and for claim 23 at page 18, lines 19-23, at page 27, lines 21-23, and at page 28, line 30 through page 29, line 3. No new matter has been added by these amendments. Applicants respectfully request entry of the present amendment.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date:

September 27, 1989

David G. Streeter

David G. Streeter, Ph. D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

62220-01622160

PF-0346 US

T-CELL RECEPTOR BETA-LIKE PROTEIN

FIELD OF THE INVENTION

This invention relates to nucleic acid and amino acid sequences of a T-cell receptor beta-like protein and to the use of these sequences in the diagnosis, prevention, and treatment of cancer and autoimmune disorders.

5

BACKGROUND OF THE INVENTION

T cells play a central role in the immune system as effectors and regulators, coupling antigen recognition and the transmission of activation signals. The diverse responses of T cells are referred to as cell-mediated immune reactions and are initiated by recognition of antigens via the T cell receptor (TCR).

10

T cells recognize a wide range of different antigens. As with B cells, a particular clonal line of T cells can only recognize a single antigen. However, unlike B cells, T cells recognize antigens only when they are presented to the TCR as peptides in a complex with major histocompatibility molecules (MHC) on the surface of antigen presenting cells. The TCR on most T cells consist of immunoglobulin-like integral membrane glycoproteins containing 2 polypeptide subunits, alpha and beta, of similar molecular weight. Each T-cell receptor subunit has an external amino terminal containing both a variable (V) domain and a constant (C) domain. The genes for the T-cell receptor subunits are constructed through somatic rearrangement of different gene segments, of which there are at least 3 types for the alpha; V, joining (J) and C domains, and at least types 4 for the beta; V, diversity (D), J and C domains. An invariant CD3 complex of polypeptides and a disulfide-linked homodimer are noncovalently associated with the TCR. These associated polypeptides are responsible for the signal transduction functions of the TCR and are also required for efficient surface expression of the intact receptor.

15

20

25

Interaction of antigen in the proper MHC context with the TCR leads to a regulated series of events resulting in differentiation, proliferation, and the acquisition of T cell immunologic function. The particular functional response depends on whether the T cell

receives co-stimulatory signals through other surface receptors and which signal transduction pathways are activated (Klausner, R. D. and Samelson, L., E. (1991) *Cell* 64: 875-878; Clevers, H. et al. (1988) *Annu. Rev. Immunol.* 6: 629-662).

The signaling cascades initiated by TCR activation include the inositol tri-phosphate/ Ca^{2+} , diacylglycerol/protein kinase C, Ras/mitogen-activated protein kinase, and the PI 3-K pathways. Components of these pathways transmit information into the nucleus to activate the genes that code for a variety of secreted factors such as IL-2, IL-4, IL-7, IL-9, IL-10, and interferon- γ , which subsequently induce the proliferation, maturation, and function of cellular components of the immune system. These factors can stimulate the induction of antibody secretion and class switching in B cells, the regulation of humoral immunity, and induction of tumorocidal and anti-inflammatory activity (Alderson, M., R., et al (1991) *J. Exp. Med.* 173: 923-930; and Weiss, A. (1991) *Annu. Rev. Genet.* 25: 487-510).

The TCR antigen repertoire is established by developmentally regulated TCR gene rearrangements and is shaped by intrathymic selection processes. Immature T cells undergo a selection and differentiation process based on antigen binding prior to leaving the thymus. Those that bind self-antigens while still in the cortex of the thymus are eliminated by apoptosis, establishing immunological tolerance. Failure to eliminate self reactive populations of cells has been shown to result in autoimmune disease. Immature T cells express both CD4 and CD8 co-receptors which assist in MHC recognition; thymic maturation produces T cells expressing one or the other of these receptors. This maturation process is dependent on the structure of the surface TCR complexes expressed. Results of animal studies indicate that the successful differentiation into single-positive (bearing either CD4 or CD8) T cells requires surface expression of fully assembled TCR complexes (Shores, E. W., et al. (1993) *J Immunol* 150 4: 1263-1275 and Olive, C. (1995) *Immunol. Cell Biol.* 73: 297-307).

Defects in TCR genes, TCR expression, and T cell subtype population levels have been noted in lymphomas, leukemias, allergic responses, and autoimmune and immunodeficiency disorders. In transgenic mice deficient in the TCR alpha and beta subunits, B cells expand, differentiate and secrete copious amounts of antibodies that are reactive towards self antigens. Graft-versus-host disease is the result of normal T cell

responses to cells perceived as foreign, as is the cytolytic destruction of virus infected and tumor cells. As more human TCR subunit genes are identified, additional specific functions of the TCR can be characterized (Yui, K. et al (1992) Eur J Immunol 22: 1693-1700; Olive, C., supra (1995); Mombaerts, P., et al (1993) Cell 75: 274-282; Wen, L., et al (1994) Nature 369 :654-658; Leiden, J., M., et al. (1986) Immunogenet. 24: 17-23; and Barber, D., F., and Lopez de Castro, J., A., Genbank accession L34734)

The discovery of a new T-cell receptor beta-like protein and the polynucleotides encoding it satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention and treatment of cancer and autoimmune disorders.

SUMMARY OF THE INVENTION

The invention features a substantially purified polypeptide, T-cell receptor beta-like protein (TCRLP), having the amino acid sequence shown in SEQ ID NO:1, or fragments thereof.

The invention further provides an isolated and substantially purified polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof and a composition comprising said polynucleotide sequence. The invention also provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the amino acid sequence SEQ ID NO:1, or fragments of said polynucleotide sequence. The invention further provides a polynucleotide sequence comprising the complement of the polynucleotide sequence encoding the amino acid sequence of SEQ ID NO:1, or fragments or variants of said polynucleotide sequence.

The invention also provides an isolated and purified sequence comprising SEQ ID NO.2 or variants thereof. In addition, the invention provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:2.

In another aspect the invention provides a composition comprising an isolated and purified polynucleotide sequence comprising the complement of SEQ ID NO:2, or fragments or variants thereof. The invention also provides a polynucleotide sequence comprising the complement of SEQ ID NO:2.

The present invention further provides an expression vector containing at least a fragment of any of the claimed polynucleotide sequences. In yet another aspect, the expression vector containing the polynucleotide sequence is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment thereof, the method comprising the steps of: a) culturing the host cell containing an expression vector containing at least a fragment of the polynucleotide sequence encoding T-cell receptor beta-like protein under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified T-cell receptor beta-like protein having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

The invention also provides a purified antagonist of the polypeptide of SEQ ID NO:1. In one aspect the invention provides a purified antibody which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

Still further, the invention provides a purified agonist of the polypeptide of SEQ ID NO:1.

The invention also provides a method for treating or preventing cancer comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising purified TCRLB.

The invention also provides a method for treating or preventing cancer comprising administering to a subject in need of such treatment an effective amount of an agonist which increases the activity of TCRLB.

The invention also provides a method for treating or preventing autoimmune disorders comprising administering to a subject in need of such treatment an effective amount of an antagonist which decreases the activity of TCRLB.

The invention also provides a method for detecting a polynucleotide which encodes T-cell receptor beta-like protein in a biological sample comprising the steps of: a) hybridizing the complement of the polynucleotide sequence which encodes SEQ ID NO:1 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and b) detecting

the hybridization complex, wherein the presence of the complex correlates with the presence of a polynucleotide encoding T-cell receptor beta-like protein in the biological sample. In one aspect the nucleic acid material of the biological sample is amplified by the polymerase chain reaction prior to hybridization.

5

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A, 1B, 1C, and 1D show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of TCRLB. The alignment was produced using MacDNASIS PRO™ software (Hitachi Software Engineering Co. Ltd. San Bruno, CA).

10 Figures 2A and 2B show the amino acid sequence alignments among TCRLP (SEQ ID NO:1), human T-cell receptor beta (GI 1100182; SEQ ID NO:3) and human T-cell receptor precursor (GI 339012; SEQ ID NO:4), produced using the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

15

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

20 It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a host cell” includes a plurality of such host cells, reference to the “antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

25 Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices,

30

and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not
5 entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

T-cell receptor beta-like protein, as used herein, refers to the amino acid sequences of substantially purified T-cell receptor beta-like protein obtained from any species, particularly
10 mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist", as used herein, refers to a molecule which, when bound to T-cell receptor beta-like protein, increases or prolongs the duration of the effect of T-cell receptor beta-like protein. Agonists may include proteins, nucleic acids, carbohydrates, or any other
15 molecules which bind to and modulate the effect of T-cell receptor beta-like protein.

An "allele" or "allelic sequence", as used herein, is an alternative form of the gene encoding T-cell receptor beta-like protein. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have
20 none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding T-cell receptor beta-like protein as used
25 herein include those with deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent T-cell receptor beta-like protein. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding T-cell receptor beta-like protein, and improper or unexpected hybridization to
30 alleles, with a locus other than the normal chromosomal locus for the polynucleotide

sequence encoding T-cell receptor beta-like protein. The encoded protein may also be "altered" and contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent T-cell receptor beta-like protein. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological or immunological activity of T-cell receptor beta-like protein is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, serine and threonine, and phenylalanine and tyrosine.

"Amino acid sequence" as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragment thereof, and to naturally occurring or synthetic molecules. Fragments of T-cell receptor beta-like protein are preferably about 5 to about 15 amino acids in length and retain the biological activity or the immunological activity of T-cell receptor beta-like protein. Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, amino acid sequence, and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

"Amplification" as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

The term "antagonist" as used herein, refers to a molecule which, when bound to T-cell receptor beta-like protein, decreases the amount or the duration of the effect of the biological or immunological activity of T-cell receptor beta-like protein. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules which decrease the effect of T-cell receptor beta-like protein.

As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant.

Antibodies that bind T-cell receptor beta-like protein polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal can be derived from the translation of RNA or synthesized chemically and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin, keyhole limpet hemocyanin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

The term "antigenic determinant", as used herein, refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense", as used herein, refers to any composition containing nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules include peptide nucleic acids and may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and block either transcription or translation. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic T-cell receptor beta-like protein, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing.

For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A".

Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands and in the design and use of PNA molecules.

A "composition comprising a given polynucleotide sequence" as used herein refers broadly to any composition containing the given polynucleotide sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding T-cell receptor beta-like protein (SEQ ID NO:1) or fragments thereof (e.g., SEQ ID NO:2 and fragments thereof) may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS) and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus", as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, has been extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly (e.g., GELVIEW™ Fragment Assembly system, GCG, Madison, WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern analysis is indicative of the presence of mRNA encoding T-cell receptor beta-like protein in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

A "deletion", as used herein, refers to a change in the amino acid or nucleotide sequence and results in the absence of one or more amino acid residues or nucleotides.

The term "derivative", as used herein, refers to the chemical modification of a nucleic

acid encoding or complementary to T-cell receptor beta-like protein or the encoded T-cell receptor beta-like protein. Such modifications include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative encodes a polypeptide which retains the biological or immunological function of the natural molecule. A derivative polypeptide is one which is modified by glycosylation, pegylation, or any similar process which retains the biological or immunological function of the polypeptide from which it was derived.

The term "homology", as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity). In the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

Human artificial chromosomes (HACs) are linear microchromosomes which may contain DNA sequences of 10K to 10M in size and contain all of the elements required for stable mitotic chromosome segregation and maintenance (Harrington, J.J. et al. (1997) Nat Genet. 15:345-355).

The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

The term "hybridization", as used herein, refers to any process by which a strand of

nucleic acid binds with a complementary strand through base pairing.

The term “hybridization complex”, as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

An “insertion” or “addition”, as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, as compared to the naturally occurring molecule.

“Microarray” refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.

The term “modulate”, as used herein, refers to a change in the activity of T-cell receptor beta-like protein. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional or immunological properties of T-cell receptor beta-like protein.

“Nucleic acid sequence” as used herein refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand.

“Fragments” are those nucleic acid sequences which are greater than 60 nucleotides in length, and most preferably includes fragments that are at least 100 nucleotides or at least 1000 nucleotides, and at least 10,000 nucleotides in length.

The term “oligonucleotide” refers to a nucleic acid sequence of at least about 6 nucleotides to about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20 to 25 nucleotides, which can be used in PCR amplification or a hybridization assay, or a microarray. As used herein, oligonucleotide is substantially

equivalent to the terms "amplimers", "primers", "oligomers", and "probes", as commonly defined in the art.

"Peptide nucleic acid", PNA as used herein, refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length
5 linked to a peptide backbone of amino acid residues which ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in the cell where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

The term "portion", as used herein, with regard to a protein (as in "a portion of a given
10 protein") refers to fragments of that protein. The fragments may range in size from five amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length T-cell receptor beta-like protein and fragments thereof.

The term "sample", as used herein, is used in its broadest sense. A biological sample
15 suspected of containing nucleic acid encoding T-cell receptor beta-like protein, or fragments thereof, or T-cell receptor beta-like protein itself may comprise a bodily fluid, extract from a cell, chromosome, organelle, or membrane isolated from a cell, a cell, genomic DNA, RNA, or cDNA(in solution or bound to a solid support, a tissue, a tissue print, and the like.

The terms "specific binding" or "specifically binding", as used herein, refers to that
20 interaction between a protein or peptide and an agonist, an antibody and an antagonist. The interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) of the protein recognized by the binding molecule. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the
25 amount of labeled A bound to the antibody.

The terms "stringent conditions" or "stringency", as used herein, refer to the conditions for hybridization as defined by the nucleic acid, salt, and temperature. These conditions are well known in the art and may be altered in order to identify or detect identical or related polynucleotide sequences. Numerous equivalent conditions comprising either low
30 or high stringency depend on factors such as the length and nature of the sequence (DNA,

immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

THE INVENTION

5 The invention is based on the discovery of a new human T-cell receptor beta-like protein (hereinafter referred to as "TCRLP"), the polynucleotides encoding TCRLP, and the use of these compositions for the diagnosis, prevention, or treatment of cancer and autoimmune disorders.

10 Nucleic acids encoding the TCRLP of the present invention were first identified in Incyte Clone 983910 from the tongue tumor cDNA library (TONGTUT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 983910 (TONGTUT01), 343545 (THYMNOT02), 1282195 (COLNNOT16), 1876350 (LEUKNOT02), 1603501 (LUNGNOT15).

15 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figs. 1A, 1B, 1C, and 1D. TCRLP is 314 amino acids in length and has one potential N-glycosylation site at N₂₀₅, four potential caseine kinase II phosphorylation sites at S₁₂₀, T₁₃₃, S₁₅₂, and S₂₃₉, and five potential protein kinase C phosphorylation sites, at S₂₈, T₃₂, T₉₅, T₁₅₉, and S₂₁₂. As shown in Figs. 2A and 2B, TCRLP
20 has chemical and structural homology with human T-cell receptor beta (GI 1100182; SEQ ID NO:3) and human T-cell receptor precursor (GI 339012; SEQ ID NO:4). In particular, TCRLP and human T-cell receptor beta (GI 1100182) share 85% identity and TCRLP and human T-cell receptor precursor (GI 339012) share 82% identity. Northern analysis shows the expression of this sequence in various libraries, most of which are which are fetal and
25 immune cell libraries.

 The invention also encompasses TCRLP variants. A preferred TCRLP variant is one having at least 80%, and more preferably at least 90%, amino acid sequence identity to the TCRLP amino acid sequence (SEQ ID NO:1) and which retains at least one biological, immunological or other functional characteristic or activity of TCRLP. A most preferred
30 TCRLP variant is one having at least 95% amino acid sequence identity to SEQ ID NO:1.

The invention also encompasses polynucleotides which encode TCRLP. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of TCRLP can be used to produce recombinant molecules which express TCRLP. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID
5 NO:2 as shown in Fig. 1.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding TCRLP, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of
10 nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring TCRLP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode TCRLP and its variants are preferably
15 capable of hybridizing to the nucleotide sequence of the naturally occurring TCRLP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding TCRLP or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which
20 particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding TCRLP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or fragments thereof,
25 which encode TCRLP and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding TCRLP or any fragment thereof.

30 Also encompassed by the invention are polynucleotide sequences that are capable of

hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

5 Methods for DNA sequencing which are well known and generally available in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proofreading
10 exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

15 The nucleic acid sequences encoding TCRLP may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In
20 particular, genomic DNA is first amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

25 Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers may be designed using commercially available software such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to
30 anneal to the target sequence at temperatures about 68°-72° C. The method uses several

restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode TCRLP may be used in recombinant DNA molecules to direct

expression of TCRLP, fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express TCRLP.

5 As will be understood by those of skill in the art, it may be advantageous to produce TCRLP-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the
10 naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter TCRLP encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR
15 reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic
20 acid sequences encoding TCRLP may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of TCRLP activity, it may be useful to encode a chimeric TCRLP protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the TCRLP encoding sequence and the heterologous protein sequence, so
25 that TCRLP may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding TCRLP may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the
30 amino acid sequence of TCRLP, or a fragment thereof. For example, peptide synthesis can

be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of TCRLP, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active TCRLP, the nucleotide sequences encoding TCRLP or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding TCRLP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding TCRLP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding TCRLP, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for TCRLP. For example, when large quantities of TCRLP are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding TCRLP may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding TCRLP may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.

An insect system may also be used to express TCRLP. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding TCRLP may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of TCRLP will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which TCRLP may be expressed (Engelhard, E.K. et al. (1994) *Proc. Nat. Acad. Sci.* 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding TCRLP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing TCRLP in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In

addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6 to 10M are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding TCRLP. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding TCRLP, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; Bethesda, MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express TCRLP may be transformed using

expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines.

These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk⁻ or apt⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding TCRLP is inserted within a marker gene sequence, transformed cells containing sequences encoding TCRLP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding

TCRLP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding TCRLP and express TCRLP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding TCRLP can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding TCRLP. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding TCRLP to detect transformants containing DNA or RNA encoding TCRLP.

A variety of protocols for detecting and measuring the expression of TCRLP, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on TCRLP is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding TCRLP include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding TCRLP, or any fragments thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled

nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding TCRLP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode TCRLP may be designed to contain signal sequences which direct secretion of TCRLP through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding TCRLP to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and TCRLP may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing TCRLP and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281) while the enterokinase cleavage site provides a means for purifying TCRLP from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of TCRLP may be produced by direct peptide synthesis using solid-phase techniques Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by

automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of TCRLP may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

5

THERAPEUTICS

Based on the chemical and structural homology among TCRLP, human T-cell receptor beta (GI 1100182) and human T-cell receptor precursor (GI 339012), TCRLP appears to be a T cell receptor beta like protein. T cell receptor beta proteins are essential to the formation of a functional T cell receptor and play a role in antigen recognition by T cells. T cell antigen recognition is crucial to all of the cell-mediated immune reactions that are effected and regulated by T cells. In addition, TCRLP is expressed primarily in cells of the immune system. Therefore, TCRLP appears to be a at cell play a role in cancer and autoimmune disorders.

Therefore, in one embodiment, TCRLP or a fragment or derivative may be administered to a subject to treat or prevent cancer. These cancers include, but are not limited to, adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma and particularly cancers of the adrenal gland, bladder, bone, brain, breast, cervix, gall bladder, gastrointestinal tract, heart, kidney, liver, lung, ovaries, pancreas, paragangliomas, parathyroid, pituitary gland, prostate, salivary gland, spleen, stomach, thymus, thyroid, testes, and uterus.

In another embodiment, a vector capable of expressing TCRLP, or a fragment or a derivative thereof, may also be administered to a subject to treat cancers including, but not limited to, those described above.

In another embodiment, an agonist of TCRLP may be administered to a subject to prevent or treat cancers including, but not limited to, those described above.

In one embodiment, an antagonist of TCRLP may be administered to a subject to prevent or treat an autoimmune disorder. Such disorders may include, but are not limited to, AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic dermatitis,

dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma. In one aspect, an antibody which specifically binds TCRLP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express TCRLP.

In another embodiment, a vector expressing the complement of the polynucleotide encoding TCRLP may be administered to a subject to treat or prevent an autoimmune disorder including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of TCRLP may be produced using methods which are generally known in the art. In particular, purified TCRLP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind TCRLP.

Antibodies to TCRLP may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with TCRLP or any fragment or

oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, 5 keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to TCRLP have an amino acid sequence consisting of at least five amino acids and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of 10 the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of TCRLP amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to TCRLP may be prepared using any technique which 15 provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the 20 splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; Takeda, S. et al. (1985) Nature 314:452-454). Alternatively, techniques 25 described for the production of single chain antibodies may be adapted, using methods known in the art, to produce TCRLP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:11120-3).

30 Antibodies may also be produced by inducing in vivo production in the lymphocyte

population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for TCRLP may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments.

Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between TCRLP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering TCRLP epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

In another embodiment of the invention, the polynucleotides encoding TCRLP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding TCRLP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding TCRLP. Thus, complementary molecules or fragments may be used to modulate TCRLP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding TCRLP.

Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in

the art can be used to construct vectors which will express nucleic acid sequence which is complementary to the polynucleotides of the gene encoding TCRLP. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

Genes encoding TCRLP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes TCRLP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions of the gene encoding TCRLP (signal sequence, promoters, enhancers, and introns). Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding TCRLP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the

following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding TCRLP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections or polycationic amino polymers (Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-66; incorporated herein by reference) may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits,

monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of TCRLP, antibodies to TCRLP, mimetics, agonists, antagonists, or inhibitors of TCRLP. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other

plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a

manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of TCRLP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example TCRLP or fragments thereof, antibodies of TCRLP, agonists, antagonists or inhibitors of TCRLP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀.

Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage

for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

5 The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug
10 combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

 Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages
15 and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

20 **DIAGNOSTICS**

 In another embodiment, antibodies which specifically bind TCRLP may be used for the diagnosis of conditions or diseases characterized by expression of TCRLP, or in assays to monitor patients being treated with TCRLP, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those
25 described above for therapeutics. Diagnostic assays for TCRLP include methods which utilize the antibody and a label to detect TCRLP in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described
30 above.

A variety of protocols including ELISA, RIA, and FACS for measuring TCRLP are known in the art and provide a basis for diagnosing altered or abnormal levels of TCRLP expression. Normal or standard values for TCRLP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to TCRLP under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric, means. Quantities of TCRLP expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding TCRLP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of TCRLP may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of TCRLP, and to monitor regulation of TCRLP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding TCRLP or closely related molecules, may be used to identify nucleic acid sequences which encode TCRLP. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding TCRLP, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the TCRLP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring TCRLP.

Means for producing specific hybridization probes for DNAs encoding TCRLP

include the cloning of nucleic acid sequences encoding TCRLP or TCRLP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes
5 may be labeled by a variety of reporter groups, for example, radionuclides such as ^{32}P or ^{35}S , or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding TCRLP may be used for the diagnosis of conditions or disorders which are associated with expression of TCRLP. Examples of such
10 conditions or disorders include adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma and particularly cancers of the adrenal gland, bladder, bone, brain, breast, cervix, gall bladder, gastrointestinal tract, heart, kidney, liver, lung, ovaries, pancreas, paragangliomas, parathyroid, pituitary gland, prostate, salivary gland, spleen, stomach, thymus, thyroid, testes, and uterus; and AIDS, Addison's disease, adult respiratory
15 distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis,
20 pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, and extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma. The polynucleotide sequences encoding TCRLP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in
25 dipstick, pin, ELISA assays or microarrays utilizing fluids or tissues from patient biopsies to detect altered TCRLP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding TCRLP may be useful in assays that detect activation or induction of various cancers, particularly those mentioned
30 above. The nucleotide sequences encoding TCRLP may be labeled by standard methods, and

added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding TCRLP in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of TCRLP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes TCRLP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding TCRLP may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'→3') and another with antisense (3'←5'),
 5 employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of TCRLP include
 10 radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and
 15 a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, an oligonucleotide derived from any of the polynucleotide sequences described herein may be used as a target in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously (to produce a transcript image), and to identify genetic variants, mutations and polymorphisms. This
 20 information will be useful in determining gene function, understanding the genetic basis of disease, diagnosing disease, and in developing and monitoring the activity of therapeutic agents (Heller, R. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-55) .

In one embodiment, the microarray is prepared and used according to the methods described in PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat.
 25 Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference.

The microarray is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides
 30 in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25

nucleotides in length. For a certain type of microarray, it may be preferable to use oligonucleotides which are only 7-10 nucleotides in length. The microarray may contain oligonucleotides which cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular
5 areas along the length of the sequence. Polynucleotides used in the microarray may be oligonucleotides that are specific to a gene or genes of interest in which at least a fragment of the sequence is known or that are specific to one or more unidentified cDNAs which are common to a particular cell type, developmental or disease state.

In order to produce oligonucleotides to a known sequence for a microarray, the gene
10 of interest is examined using a computer algorithm which starts at the 5' or more preferably at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray. The "pairs" will be
15 identical, except for one nucleotide which preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid
20 support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or
25 slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144
30 oligonucleotides, or any other number between two and one million which lends itself to the

efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray so that the probe sequences hybridize to complementary oligonucleotides of the microarray. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies on the sequences, mutations, variants, or polymorphisms among samples.

In another embodiment of the invention, the nucleic acid sequences which encode TCRLP may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome or to artificial chromosome constructions, such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) *Blood Rev.* 7:127-134, and Trask, B.J. (1991) *Trends Genet.* 7:149-154.

Fluorescent in situ hybridization (FISH as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in various scientific journals or at Online Mendelian Inheritance in Man (OMIM). Correlation between the location of the gene encoding TCRLP on a physical chromosomal map and a specific disease, or predisposition to

a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques
 5 such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable
 10 information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention
 15 may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, TCRLP, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be
 20 free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between TCRLP and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest
 25 as described in published PCT application WO84/03564. In this method, as applied to TCRLP large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with TCRLP, or fragments thereof, and washed. Bound TCRLP is then detected by methods well known in the art. Purified TCRLP can also be coated directly onto plates for use in the aforementioned
 30 drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture

the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding TCRLP specifically compete with a test compound for binding TCRLP. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with TCRLP.

In additional embodiments, the nucleotide sequences which encode TCRLP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES

I TONGTUT01 cDNA Library Construction

The TONGTUT01 cDNA library was constructed from tongue tumor tissue obtained from a 36-year-old Caucasian male (specimen #0065B; Mayo Clinic, Rochester MN) during a hemiglossectomy. The pathology report indicated recurrent invasive grade 2 squamous-cell carcinoma forming a mass 2.5 x 2 x 1.3 cm in the right tongue.

The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron-PT 3000 (Brinkmann Instruments, Inc. Westbury NY) in guanidinium isothiocyanate solution. The lysates were extracted once with acid phenol at pH 4.0 using Stratagene's RNA isolation protocol (Stratagene Inc, San Diego CA). The RNA was extracted twice with an equal volume of acid phenol, reprecipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in DEPC-treated water and DNase treated for 25 min at 37°C. mRNAs were isolated using the Qiagen Oligotex kit (QIAGEN Inc.) and used to construct the cDNA library.

The mRNA was handled according to the recommended protocols in the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. #18248-013, Gibco/BRL). cDNAs were fractionated on a Sepharose CL4B column (Cat. #275105-01, Pharmacia), and those cDNAs exceeding 400 bp were ligated into pSport I. The plasmid pSport I was

subsequently transformed into DH5a™ competent cells (Cat. #18258-012, Gibco/BRL).

II Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96
5 Plasmid Kit for Rapid Extraction Alkaline Lysis Plasmid Minipreps (Catalog #26173,
QIAGEN, Inc.). The recommended protocol was employed except for the following changes:
1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog #22711, Gibco/BRL)
with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were
incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis
10 buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended
in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a
96-well block for storage at 4° C.

The cDNAs were sequenced by the method of Sanger et al. (1975, J. Mol. Biol.
94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with
15 Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied
Biosystems 377 DNA Sequencing Systems.

III Homology Searching of cDNA Clones and Their Deduced Proteins

The nucleotide sequences of the Sequence Listing or amino acid sequences deduced
20 from them were used as query sequences against databases such as GenBank, SwissProt,
BLOCKS, and Pima II. These databases which contain previously identified and annotated
sequences were searched for regions of homology (similarity) using BLAST, which stands
for Basic Local Alignment Search Tool (Altschul SF (1993) J Mol Evol 36:290-300;
Altschul, SF et al (1990) J Mol Biol 215:403-10).

25 BLAST produces alignments of both nucleotide and amino acid sequences to
determine sequence similarity. Because of the local nature of the alignments, BLAST is
especially useful in determining exact matches or in identifying homologs which may be of
prokaryotic (bacterial) or eukaryotic (animal, fungal or plant) origin. Other algorithms such
as the one described in Smith RF and TF Smith (1992 Protein Engineering 5:35-51),
30 incorporated herein by reference, can be used when dealing with primary sequence patterns

and secondary structure gap penalties. As disclosed in this application, the minimum length of the sequences in the Sequence Listing is 49 nucleotides, and the upper limit of uncalled bases where N is recorded rather than A, C, G, or T is 12%.

The BLAST approach, as detailed in Karlin and Altschul (1993; Proc Nat Acad Sci 90:5873-7) and incorporated herein by reference searches matches between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. In this application, threshold was set at 10^{-25} for nucleotides and 10^{-14} for peptides.

Incyte nucleotide sequence were searched against the GenBank databases for primate (pri), rodent (rod), and mammalian sequences (mam), and deduced amino acid sequences from the same clones are searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp) and eukaryote (eukp), for homology. The relevant database for a particular match were reported as a Gxxxx±p (where xxx is pri, rod, etc and if present, p = peptide) as shown in Table 1.

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., supra).

Analogous computer techniques using BLAST (Altschul, S.F. (1993) *J.Mol.Evol.* 36:290-300; Altschul, S.F. et al. (1990) *J.Mol.Evol.* 215:403-410) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

100

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be

exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding TCRLP occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of TCRLP Encoding Polynucleotides

The nucleic acid sequence of the Incyte Clone 983910 was used to design oligonucleotide primers for extending a partial nucleotide sequence to full length. One primer was synthesized to initiate extension in the antisense direction, and the other was synthesized to extend sequence in the sense direction. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be about 22 to about 30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures of about 68° to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (Gibco/BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

Step 1 94° C for 1 min (initial denaturation)

- | | | |
|----|---------|--|
| | Step 2 | 65° C for 1 min |
| | Step 3 | 68° C for 6 min |
| | Step 4 | 94° C for 15 sec |
| | Step 5 | 65° C for 1 min |
| 5 | Step 6 | 68° C for 7 min |
| | Step 7 | Repeat step 4-6 for 15 additional cycles |
| | Step 8 | 94° C for 15 sec |
| | Step 9 | 65° C for 1 min |
| | Step 10 | 68° C for 7:15 min |
| 10 | Step 11 | Repeat step 8-10 for 12 cycles |
| | Step 12 | 72° C for 8 min |
| | Step 13 | 4° C (and holding) |

A 5-10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low
 15 concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were
 successful in extending the sequence. Bands thought to contain the largest products were
 excised from the gel, purified using QIAQuick™ (QIAGEN Inc., Chatsworth, CA), and
 trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer,
 20 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture
 was incubated at room temperature for 2-3 hours or overnight at 16° C. Competent E. coli
 cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and
 cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at
 37° C, the E. coli mixture was plated on Luria Bertani (LB)-agar (Sambrook et al., supra)
 25 containing 2x Carb. The following day, several colonies were randomly picked from each
 plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an
 appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l
 of each overnight culture was transferred into a non-sterile 96-well plate and after dilution
 1:10 with water, 5 μ l of each sample was transferred into a PCR array.

30 For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4
 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers
 used for the extension reaction were added to each well. Amplification was performed using
 the following conditions:

- | | |
|--------|------------------|
| Step 1 | 94° C for 60 sec |
|--------|------------------|

- | | | |
|---|--------|--|
| | Step 2 | 94° C for 20 sec |
| | Step 3 | 55° C for 30 sec |
| | Step 4 | 72° C for 90 sec |
| | Step 5 | Repeat steps 2-4 for an additional 29 cycles |
| 5 | Step 6 | 72° C for 180 sec |
| | Step 7 | 4° C (and holding) |

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequence of SEQ ID NO:2 is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

15 VI Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphorimager cassette (Molecular Dynamics,

Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

VII Microarrays

To produce oligonucleotides for a microarray, the nucleotide sequence described
 5 herein is examined using a computer algorithm which starts at the 3' end of the nucleotide
 sequence. The algorithm identifies oligomers of defined length that are unique to the gene,
 have a GC content within a range suitable for hybridization, and lack predicted secondary
 structure that would interfere with hybridization. The algorithm identifies 20 sequence-
 specific oligonucleotides of 20 nucleotides in length (20-mers). A matched set of
 10 oligonucleotides is created in which one nucleotide in the center of each sequence is altered.
 This process is repeated for each gene in the microarray, and double sets of twenty 20 mers
 are synthesized and arranged on the surface of the silicon chip using a light-directed chemical
 process (Chee, M. et al., PCT/WO95/11995, incorporated herein by reference).

In the alternative, a chemical coupling procedure and an ink jet device are used to
 15 synthesize oligomers on the surface of a substrate (Baldeschweiler, J.D. et al.,
 PCT/WO95/25116, incorporated herein by reference). In another alternative, a "gridded"
 array analogous to a dot (or slot) blot is used to arrange and link cDNA fragments or
 oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV,
 mechanical or chemical bonding procedures. An array may be produced by hand or using
 20 available materials and machines and contain grids of 8 dots, 24 dots, 96 dots, 384 dots, 1536
 dots or 6144 dots. After hybridization, the microarray is washed to remove nonhybridized
 probes, and a scanner is used to determine the levels and patterns of fluorescence. The
 scanned images are examined to determine degree of complementarity and the relative
 abundance of each oligonucleotide sequence on the micro-array.

VIII Complementary Polynucleotides

Sequence complementary to the TCRLP-encoding sequence, or any part thereof, is
 used to decrease or inhibit expression of naturally occurring TCRLP. Although use of
 oligonucleotides comprising from about 15 to about 30 base-pairs is described, essentially the
 30 same procedure is used with smaller or larger sequence fragments. Appropriate

oligonucleotides are designed using Oligo 4.06 software and the coding sequence of TCRLP, SEQ ID NO:1. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the TCRLP-encoding transcript.

IX Expression of TCRLP

Expression of TCRLP is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector is also used to express TCRLP in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of TCRLP into the bacterial growth media which can be used directly in the following assay for activity.

X Demonstration of TCRLP Activity

TCRLP activity may be demonstrated by stimulating a TCRLP transformed cell line and assaying the induction of interleukin-2 (IL-2). A mammalian cell line such as COS or Jurket (ATCC) is transfected with eukaryotic expression vectors encoding TCRLP.

Eukaryotic expression vectors are commercially available, and the techniques to introduce them into cells are well known to those skilled in the art. The cells are maintained in RPMI media with 10% fetal bovine serum, 100 units/ml penicillin, 100 μ g/ml streptomycin sulfate, and 2 mM glutamine, at 37 °C in a humidified 5% CO atmosphere. The transformed cells are incubated for 48-72 hours after transformation under conditions appropriate for the cell line to allow expression and accumulation of TCRLP. After the incubation period the cells are

activated by the addition of 2.5 µg/ml phytohemagglutinin (Boehringer Mannheim) to the medium. Samples of the medium are analyzed at 24, 48, and 72 hours for the presence of IL-2 by ELISA using anti-IL-2 polyclonal IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The results are evaluated by comparison with mock-transfected and unstimulated cell controls.

XI Production of TCRLP Specific Antibodies

TCRLP that is substantially purified using PAGE electrophoresis (Sambrook, supra), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (supra), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for anti-peptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio iodinated, goat anti-rabbit IgG.

XII Purification of Naturally Occurring TCRLP Using Specific Antibodies

Naturally occurring or recombinant TCRLP is substantially purified by immunoaffinity chromatography using antibodies specific for TCRLP. An immunoaffinity column is constructed by covalently coupling TCRLP antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing TCRLP is passed over the immunoaffinity column, and the column

is washed under conditions that allow the preferential absorbance of TCRLP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/TCRLP binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and TCRLP is collected.

5

XIII Identification of Molecules Which Interact with TCRLP

TCRLP or biologically active fragments thereof are labeled with ¹²⁵I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled TCRLP, washed and any wells with labeled TCRLP complex are assayed. Data obtained using different concentrations of TCRLP are used to calculate values for the number, affinity, and association of TCRLP with the candidate molecules.

10

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

15

20

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Hillman, Jennifer L.
Corley, Neil C.
- (ii) TITLE OF THE INVENTION: T-CELL RECEPTOR BETA-LIKE PROTEIN
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Herewith
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0346 US
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 415-855-0555
 - (B) TELEFAX: 415-845-4166
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 314 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY: TONGTUT01
 - (B) CLONE: 983910
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

65250 " 04550460

Met Gly Thr Arg Leu Leu Cys Trp Ala Ala Leu Cys Leu Leu Gly Ala
 1 5 10 15
 Asp His Thr Gly Ala Gly Val Ser Gln Thr Pro Ser Asn Lys Val Thr
 20 25 30
 Glu Lys Gly Lys Asp Val Glu Leu Arg Cys Asp Pro Ile Ser Gly His
 35 40 45
 Thr Ala Leu Tyr Trp Tyr Arg Gln Ser Leu Gly Gln Gly Pro Glu Phe
 50 55 60
 Leu Ile Tyr Phe Gln Gly Thr Gly Ala Ala Asp Asp Ser Gly Leu Pro
 65 70 75 80
 Asn Asp Arg Phe Phe Ala Val Arg Pro Glu Gly Ser Val Ser Thr Leu
 85 90 95
 Lys Ile Gln Arg Thr Glu Gln Gly Asp Ser Ala Ala Tyr Leu Arg Ala
 100 105 110
 Gly Val Ala Gly Trp Ser Ser Tyr Asn Glu Gln Tyr Phe Gly Pro
 115 120 125
 Gly Thr Arg Leu Thr Val Leu Glu Asp Leu Lys Asn Val Phe Pro Pro
 130 135 140
 Glu Val Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln
 145 150 155 160
 Lys Ala Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val
 165 170 175
 Glu Leu Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser
 180 185 190
 Thr Asp Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg
 195 200 205
 Tyr Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn
 210 215 220
 Pro Arg Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu
 225 230 235 240
 Asn Asp Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val
 245 250 255
 Ser Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser
 260 265 270
 Tyr Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu
 275 280 285
 Gly Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met
 290 295 300
 Ala Met Val Lys Arg Lys Asp Ser Arg Gly
 305 310

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1200 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: TONGTUT01
- (B) CLONE: 983910

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTAAAGCTCC	CATCCTGCCC	TGACTCTGTC	ATGGGCACCA	GGCTCCTCTG	CTGGGCAGCC	60
CTGTGCCTCC	TGGGGGCAGA	TCACACAGGT	GCTGGAGTCT	CCCAGACCCC	CAGTAACAAG	120
GTCACAGAGA	AGGGAAAAGA	TGTAGAGCTC	AGGTGTGATC	CAATTTTCAGG	TCATACTGCC	180
CTTTACTGGT	ACCGACAAAG	CCTGGGGCAG	GGCCCAGAGT	TTCTAATTTA	CTTCCAAGGC	240
ACGGGTGCGG	CAGATGACTC	AGGGCTGCCC	AACGATCGGT	TCTTTGCAGT	CAGGCCTGAG	300
GGATCCGTCT	CTACTCTGAA	GATCCAGCGC	ACAGAGCAGG	GGGACTCAGC	CGCGTATCTC	360

```

CGTGCCGGCG TTGCGGCGGG ATGGAGCTCC TACAATGAGC AGTATTTTGG CCCAGGCACC 420
CGGCTGACAG TGCTAGAGGA CCTGAAAAAC GTGTTCCCAC CCGAGGTCGC TGTGTTTGAG 480
CCATCAGAAG CAGAGATCTC CCACACCCAA AAGGCCACAC TGGTGTGCCT GGCCACAGGC 540
TTCTACCCCG ACCACGTGGA GCTGAGCTGG TGGGTGAATG GGAAGGAGGT GCACAGTGGG 600
GTCAGCACAG ACCCGCAGCC CCTCAAGGAG CAGCCCCGCC TCAATGACTC CAGATACTGC 660
CTGAGCAGCC GCCTGAGGGT CTCGGCCACC TTCTGGCAGA ACCCCCGCAA CCACTTCCGC 720
TGTCAAGTCC AGTTCTACGG GCTCTCGGAG AATGACGAGT GGACCCAGGA TAGGGCCAAA 780
CCTGTCACCC AGATCGTCAG CGCCGAGGCC TGGGGTAGAG CAGACTGTGG CTTACCTCC 840
GAGTCTTACC AGCAAGGGGT CCTGTCTGCC ACCATCCTCT ATGAGATCTT GCTAGGGAAG 900
GCCACCTTGT ATGCCGTGCT GGTCAAGTGC CTCGTGCTGA TGGCCATGGT CAAGAGAAAG 960
GATTCCAGAG GCTAGCTCCA AAACCATCCC AGGTCATTCT TCATCCTCAC CCAGGATTCT 1020
CCTGTACCTG CTCCCAATCT GTGTTCTTAA AAGTGATTCT CACTCTGCTT CTCATCTCCT 1080
ACTTACATGA ATACTTCTCT CTTTTTCTG TTCCCTGAA GATTGAGCTC CCAACCCCA 1140
AGTACGAAAT AGGCTAAACC AATAAAAAAT TGTGTGTTGG GCCTGGTTGC AAAAAAAAAA 1200

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 311 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 1100182

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Gly Thr Ser Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala
 1          5          10          15
Asp His Ala Asp Thr Gly Val Ser Gln Asn Pro Arg His Lys Ile Thr
          20          25          30
Lys Arg Gly Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His
          35          40          45
Asn Arg Leu Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe
          50          55          60
Leu Thr Tyr Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu
          65          70          75          80
Ser Asp Arg Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu
          85          90          95
Glu Ile Gln Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala
          100          105          110
Ser Ser Pro Gly Thr Ser Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg
          115          120          125
Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala
          130          135          140
Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr
          145          150          155          160
Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser
          165          170          175
Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
          180          185          190
Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu
          195          200          205
Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn
          210          215          220
His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu
          225          230          235          240
Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu
          245          250          255

```

```

Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln
      260      265      270
Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala
      275      280      285
Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val
      290      295      300
Lys Arg Lys Asp Ser Arg Gly
305      310

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 310 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 339012

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Gly Thr Ser Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala
 1      5      10      15
Asp His Ala Asp Thr Gly Val Ser Gln Asn Pro Arg His Asn Ile Thr
      20      25      30
Lys Arg Gly Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His
      35      40      45
Asn Arg Leu Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe
      50      55      60
Leu Thr Tyr Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu
      65      70      75      80
Ser Asp Arg Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu
      85      90      95
Glu Ile Gln Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala
      100      105      110
Ser Ser Leu Ala Gly Leu Asn Gln Pro Gln His Phe Gly Asp Gly Thr
      115      120      125
Arg Leu Ser Ile Leu Glu Asp Leu Asn Lys Val Phe Pro Pro Glu Val
      130      135      140
Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala
      145      150      155      160
Thr Leu Val Cys Leu Ala Thr Gly Ile Phe Pro Asp His Val Glu Leu
      165      170      175
Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp
      180      185      190
Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys
      195      200      205
Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg
      210      215      220
Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp
      225      230      235      240
Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala
      245      250      255
Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln
      260      265      270
Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys
      275      280      285
Ala Thr Met Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met
      290      295      300

```


PF-0346 US

Val Lys Arg Lys Asp Phe
305 310

What is claimed is:

1. A substantially purified T-cell receptor beta-like protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.

5

2. A variant of T-cell receptor beta-like protein having at least 90% amino acid identity to SEQ ID NO:1 and which retains at least one functional characteristic of T-cell receptor beta-like protein.

10

3. An isolated and purified polynucleotide sequence encoding the T-cell receptor beta-like protein of claim 1 or fragments or variants of said polynucleotide sequence.

4. A composition comprising the polynucleotide sequence of claim 3.

15

5. A polynucleotide sequence which hybridizes to the polynucleotide sequence of claim 3.

6. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 3 or fragments or variants thereof.

20

7. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or fragments or variants thereof.

8. A composition comprising the polynucleotide sequence of claim 7.

25

9. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 7.

10. An expression vector containing at least a fragment of the polynucleotide sequence of claim 3.

30

11. A host cell containing the vector of claim 10.

12. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, or a fragment thereof, the method comprising the steps of:

- 5 a) culturing the host cell of claim 11 under conditions suitable for the expression of the polypeptide; and
- b) recovering the polypeptide from the host cell culture.

13. A pharmaceutical composition comprising a substantially purified T-cell
10 receptor beta-like protein having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

14. A purified antibody which specifically binds to the polypeptide of claim 1.

15 15. A purified agonist of the polypeptide of claim 1.

16. A purified antagonist of the polypeptide of claim 1.

17. A method for treating a cancer comprising administering to a subject in need
20 of such treatment an effective amount of the pharmaceutical composition of claim 13.

18. A method for treating a cancer comprising administering to a subject in need of such treatment an effective amount of the agonist of claim 15.

25 19. A method for treating an autoimmune disorder comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

20. A method for detecting a polynucleotide which encodes T-cell receptor beta-like protein in a biological sample comprising the steps of:

- 30 a) hybridizing the polynucleotide of claim 6 to nucleic acid material of a

biological sample, thereby forming a hybridization complex; and

b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding T-cell receptor beta-like protein in said biological sample.

5

21. The method of claim 18 wherein the nucleic acid material is amplified by the polymerase chain reaction prior to hybridization.

04630460

ABSTRACT OF THE DISCLOSURE

The invention provides a human T-cell receptor beta-like protein (TCRLP) and
5 polynucleotides which identify and encode TCRLP. The invention also provides expression
vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods
for treating disorders associated with expression of TCRLP.

65 2000 04 05 09 00

	9	18	27	36	45	54
5'	GTA AAG CTC CCA TCC TGC CCT GAC TCT GTG ATG GGC ACC AGG CTC CTC TGC TGG	M	G	T	R	L L C W
	63	72	81	90	99	108
GCA GCC CTG TGC CTC CTG GGG GCA GAT CAC ACA GGT GGT GGA GTC TTC CAG ACC	A	L C L L G A D H T G A G V S Q T				
	117	126	135	144	153	162
CCC AGT AAC AAG GTC ACA GAG AAG GGA AAA GAT GTA GAG CTC AGG TGT GAT CCA	P	S N K V T E K G G A A A GAT GTA GAG CTC AGG TGT GAT CCA				
	171	180	189	198	207	216
ATT TCA GGT CAT ACT GCC CTT TAC TGG TAC CGA CAA AGC CTG GGG CAG GGC CCA	I	S G H T A L Y W Y R Q S L G Q G P				
	225	234	243	252	261	270
GAG TTT CTA ATT TAC TTC CAA GGC ACG GGT GCG GCA GAT GAC TCA GGG CTG CCC	E	F L I Y F Q G T G A A D D S G L P				
	279	288	297	306	315	324
AAC GAT CGG TTC TTT GCA GTC AGG CCT GAG GGA TCC GTC TCT ACT CTG AAG ATC	N	D R F F A V A V R P E G S V S T L K I				
	333	342	351	360	369	378
CAG CGC ACA GAG CAG GGG GAC TCA GCC GCG TAT CTC CGT GCC GGC GTT GCG GCG	Q	R T E Q G G D S A A Y L R A G V A A				

FIGURE 1A

387	GGA	TGG	AGC	TCC	TAC	AAT	GAG	CAG	TAT	TTT	GGC	CCA	GGC	ACC	CGG	CTG	ACA	GTG
	G	W	S	S	Y	N	E	Q	Y	F	G	P	G	T	R	L	T	V
									405			414			423		432	
396																		
441	CTA	GAG	GAC	CTG	AAA	AAC	GTG	TTC	CCA	CCC	GAG	GTC	GCT	GTG	TTT	GAG	CCA	TCA
	L	E	D	L	K	N	V	F	P	P	E	V	A	V	F	E	P	S
									459			468			477		486	
450																		
495	GAA	GCA	GAG	ATC	TCC	CAC	ACC	CAA	AAG	GCC	ACA	CTG	GTG	TGC	CTG	GCC	ACA	GGC
	E	A	E	I	S	H	T	Q	K	A	T	L	V	C	L	A	T	G
									513			522			531		540	
504																		
549	TTC	TAC	CCC	GAC	CAC	GTG	GAG	CTG	AGC	TGG	TGG	GTG	AAT	GGG	AAG	GAG	GTG	CAC
	F	Y	P	D	H	V	E	L	S	W	W	V	N	G	K	E	V	H
									567			576			585		594	
558																		
603	AGT	GGG	GTC	AGC	ACA	GAC	CCG	CAG	CCC	CTC	AAG	GAG	CAG	CCC	GCC	CTC	AAT	GAC
	S	G	V	S	T	D	P	Q	P	L	K	E	Q	P	A	L	N	D
									621			630			639		648	
612																		
657	TCC	AGA	TAC	TGC	CTG	AGC	AGC	CGC	CTG	AGG	GTC	TGC	GCC	ACC	TTC	TGG	CAG	AAC
	S	R	Y	C	L	S	S	R	L	R	V	S	A	T	F	W	Q	N
									675			684			693		702	
666																		
711	CCC	CGC	AAC	CAC	TTC	CGC	TGT	CAA	GTC	CAG	TTC	TAC	GGG	CTC	TCG	GAG	AAT	GAC
	P	R	N	H	F	R	C	Q	V	Q	F	Y	G	L	S	E	N	D
									729			738			747		756	
720																		

FIGURE 1B

765	774	783	792	801	810
GAG TGG ACC CAG GAT AGG GCC AAA CCT GTC ACC CAG ATC GTC AGC GCC GAG GCC					
E W T Q D R A K P V T Q I V S A E A					
819	828	837	846	855	864
TGG GGT AGA GCA GAC TGT GGC TTC ACC TCC GAG TCT TAC CAG CAA GGG GTC CTG					
W G R A D C G F T S E S Y Q G V L					
873	882	891	900	909	918
TCT GCC ACC ATC CTC TAT GAG ATC TTG CTA GGG AAG GCC ACC TTG TAT GCC GTG					
S A T I L Y E I L L G K A T L Y A V					
927	936	945	954	963	972
CTG GTC AGT GCC CTC GTG CTG ATG GCC ATG GTC AAG AGA AAG GAT TCC AGA GGC					
L V S A L V L M A M V K R K D S R G					
981	990	999	1008	1017	1026
TAG CTC CAA AAC CAT CCC AGG TCA TTC TTC ATC CTC ACC CAG GAT TCT CCT GTA					
1035	1044	1053	1062	1071	1080
CCT GCT CCC AAT CTG TGT TCC TAA AAG TGA TTC TCA CTC TGC TTC TCA TCT CCT					
1089	1098	1107	1116	1125	1134
ACT TAC ATG AAT ACT TCT CTC TTT TTT CTG TTT CCC TGA AGA TTG AGC TCC CAA					

FIGURE 1C

662260" 04630460

1143	1152	1161	1170	1179	1188
CCC CCA AGT ACG AAA TAG GCT AAA CCA ATA AAA AAT TGT GTG TTG GGC CTG GTT					

1197
GCA AAA AAA AAA 3'

FIGURE 1D

1	M	G	T	R	L	C	W	A	A	L	C	L	L	G	A	D	H	T	G	A	G	V	S	Q	T	P	S	N	K	V	T	E	K	G	K	D	V	E	L	983910		
1	M	G	T	S	L	L	C	W	M	A	L	C	L	L	G	A	D	H	A	D	T	G	V	S	Q	N	P	R	H	K	I	T	K	R	G	Q	N	V	T	F	GI 1100182	
1	M	G	T	S	L	L	C	W	M	A	L	C	L	L	G	A	D	H	A	D	T	G	V	S	Q	N	P	R	H	N	I	T	K	R	G	Q	N	V	T	F	GI 339012	
41	R	C	D	P	I	S	G	H	T	A	L	Y	W	Y	R	Q	S	L	G	Q	G	P	E	F	L	I	Y	F	Q	G	T	G	A	A	D	D	S	G	L	P	983910	
41	R	C	D	P	I	S	E	H	N	R	L	Y	W	Y	R	Q	T	L	G	Q	G	P	E	F	L	T	Y	F	Q	N	E	A	Q	L	E	K	S	R	L	L	GI 1100182	
41	R	C	D	P	I	S	E	H	N	R	L	Y	W	Y	R	Q	T	L	G	Q	G	P	E	F	L	T	Y	F	Q	N	E	A	Q	L	E	K	S	R	L	L	GI 339012	
81	N	D	R	F	F	A	V	R	P	E	G	S	V	S	T	L	K	I	Q	R	T	E	Q	G	D	S	A	A	Y	L	R	A	G	V	A	A	G	W	S	983910		
81	S	D	R	F	S	A	E	R	P	K	G	S	F	S	T	L	E	I	Q	R	T	E	Q	G	D	S	A	M	Y	L	C	A	S	S	-	P	G	T	S	-	GI 1100182	
81	S	D	R	F	S	A	E	R	P	K	G	S	F	S	T	L	E	I	Q	R	T	E	Q	G	D	S	A	M	Y	L	C	A	S	S	L	A	G	L	N	-	GI 339012	
121	Y	N	E	Q	Y	F	G	P	G	T	R	L	T	V	L	E	D	L	K	N	V	F	P	P	E	V	A	V	F	F	E	P	S	E	A	E	I	S	H	T	Q	983910
119	-	Y	E	Q	Y	F	G	P	G	T	R	L	T	V	L	E	D	L	K	N	V	F	P	P	E	V	A	V	F	F	E	P	S	E	A	E	I	S	H	T	Q	GI 1100182
120	-	Q	P	Q	H	F	G	D	G	T	R	L	S	I	L	E	D	L	N	K	V	F	P	P	E	V	A	V	F	F	E	P	S	E	A	E	I	S	H	T	Q	GI 339012
161	K	A	T	L	V	C	L	A	T	G	F	Y	P	D	H	V	E	L	S	W	W	V	N	G	K	E	V	H	S	G	V	S	T	D	P	Q	P	L	K	E	983910	
158	K	A	T	L	V	C	L	A	T	G	F	Y	P	D	H	V	E	L	S	W	W	V	N	G	K	E	V	H	S	G	V	S	T	D	P	Q	P	L	K	E	GI 1100182	
159	K	A	T	L	V	C	L	A	T	G	I	F	P	D	H	V	E	L	S	W	W	V	N	G	K	E	V	H	S	G	V	S	T	D	P	Q	P	L	K	E	GI 339012	
201	Q	P	A	L	N	D	S	R	Y	C	L	S	S	R	L	R	V	S	A	T	F	W	Q	N	P	R	N	H	F	R	C	Q	V	Q	F	Y	G	L	S	E	983910	
198	Q	P	A	L	N	D	S	R	Y	C	L	S	S	R	L	R	V	S	A	T	F	W	Q	N	P	R	N	H	F	R	C	Q	V	Q	F	Y	G	L	S	E	GI 1100182	
199	Q	P	A	L	N	D	S	R	Y	C	L	S	S	R	L	R	V	S	A	T	F	W	Q	N	P	R	N	H	F	R	C	Q	V	Q	F	Y	G	L	S	E	GI 339012	

FIGURE 2A

66'260" Cholesterol

241	N	D	E	W	T	Q	D	R	A	K	P	V	T	Q	I	V	S	A	E	A	W	G	R	A	D	C	G	F	T	S	E	S	Y	Q	Q	G	V	L	S	A	983910
238	N	D	E	W	T	Q	D	R	A	K	P	V	T	Q	I	V	S	A	E	A	W	G	R	A	D	C	G	F	T	S	E	S	Y	Q	Q	G	V	L	S	A	GI 1100182
239	N	D	E	W	T	Q	D	R	A	K	P	V	T	Q	I	V	S	A	E	A	W	G	R	A	D	C	G	F	T	S	V	S	Y	Q	Q	G	V	L	S	A	GI 339012
281	T	I	L	Y	E	I	L	L	G	K	A	T	L	Y	A	V	L	V	S	A	L	V	L	M	A	M	V	K	R	K	D									983910	
278	T	I	L	Y	E	I	L	L	G	K	A	T	L	Y	A	V	L	V	S	A	L	V	L	M	A	M	V	K	R	K	D	S	R	G					GI 1100182		
279	T	I	L	Y	E	I	L	L	G	K	A	T	M	Y	A	V	L	V	S	A	L	V	L	M	A	M	V	K	R	K	D	F							GI 339012		

FIGURE 2B

**DECLARATION AND POWER OF ATTORNEY FOR
UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe that I am the original, first and sole inventor (if only one name is listed below)
or an original, first and joint inventor (if more than one name is listed below) of the subject
matter which is claimed and for which a United States patent is sought on the invention entitled

T-CELL RECEPTOR BETA-LIKE PROTEIN

the specification of which:

/X/ is attached hereto.

/ was filed on _____ as application Serial No. _____ and if this
box contains an X /, was amended on _____.

/ was filed as Patent Cooperation Treaty international application No. _____ on
_____, 19____, if this box contains an X /, was amended on under Patent Cooperation
Treaty Article 19 on _____ 19____, and if this box contains an X /, was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified
specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of
this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any
foreign application(s) for patent or inventor's certificate indicated below and of any Patent
Cooperation Treaty international applications(s) designating at least one country other than the
United States indicated below and have also identified below any foreign application(s) for patent
or inventor's certificate and Patent Cooperation Treaty international application(s) designating at
least one country other than the United States for the same subject matter and having a filing date
before that of the application for said subject matter the priority of which is claimed:

Country	Number	Filing Date	Priority Claimed
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
_____	_____	_____

I hereby appoint the following:

LUCY J. BILLINGS
MICHAEL C. CERRONE

Registration No. 36,749
Registration No. 39,132

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

LUCY J. BILLINGS, ESQ.
INCYTE PHARMACEUTICALS, INC.
3174 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 415-855-0555 FAX: 415-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States


652260 "0463460

Docket No.: PF-0346 US


Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

***IMPORTANT:** Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

**Sole Inventor or
First Joint Inventor:**

Full name: **JENNIFER L. HILLMAN**
Signature: 
Date: July 16, 1997
Citizenship: United States of America
Residence: Mountain View, California
P.O. Address: 230 Monroe Drive, #12
Mountain View, CA 94040

Second Joint Inventor:

Full name: **NEIL C. CORLEY**
Signature: 
Date: July 16, 1997
Citizenship: United States of America
Residence: Mountain View, California
P.O. Address: 1240 Dale Avenue, #30
Mountain View, CA 94040

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 7/30/98.

By: Peggy Fazzio

Printed: Peggy Fazzio

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: T-CELL RECEPTOR BETA-LIKE PROTEIN

Serial No.: 08/897,097

Filing Date: July 18, 1997

Examiner: M. Lubet

Group Art Unit: 1644

Assistant Commissioner for Patents
Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY

Sir:

I hereby appoint the following attorneys, whose post office address is 3174 Porter Drive, Palo Alto, California 94304, as associate attorneys in the above-entitled application, to prosecute this application, to make alterations and amendments therein, and to transact all business in the Patent and Trademark Office connected therewith:

Sheela Mohan-Peterson
Colette C. Muenzen
Karen J. Zeller

Registration No. 41,201
Registration No. 39,784
Registration No. 37,071

Please continue to address all future communications to:

Legal Department
Incyte Pharmaceuticals, Inc.
3174 Porter Drive
Palo Alto, California 94304

Respectfully submitted,
INCYTE PHARMACEUTICALS, INC.

Date: April 29, 1998

Lucy J. Billings
Lucy J. Billings
Reg. No. 36,749

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

"Express Mail" mailing label number EL 315 814 217 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 9-27-99

By: _____

Printed: _____

Nancy Ramos

 NANCY RAMOS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: T-CELL RECEPTOR PROTEIN (AS AMENDED)

Serial No.: To Be Assigned

Filing Date:

Herewith

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Assistant Commissioner for Patents
 Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. §3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Pharmaceuticals, Inc., having a principal place of business located at 3174 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8648, Frame 0077, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Narinder S. Banait

Reg. No. 43,482

Adam Warwick Bell

Reg. No. 43,490

Lucy J. Billings

Reg. No. 36,749

Michael C. Cerrone

Reg. No. 39,132

Diana Hamlet-Cox

Reg. No. 33,302

Colette C. Muenzen

Reg. No. 39,784

Lynn E. Murry

Reg. No. 42,918

Danielle M. Pasqualone
Susan K. Sather
David G. Streeter

Reg. No. 43,847
Reg. No. 44,316
Reg. No. 43,168

Please direct all correspondence to:

Legal Department
Incyte Pharmaceuticals, Inc.
3174 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: David G. Streeter, Ph.D.,
Incyte Pharmaceuticals, Inc., Phone: (650) 845-5741 Fax: (650) 849-8886.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE PHARMACEUTICALS, INC.

Date: September 24, 1999

By: Lee Bendekgey
Lee Bendekgey
VP, General Counsel/Corporate Secretary